BioNTech SE
BNTX
$93.66
$0.320.34%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.96% | 11.45% | 6.95% | 7.44% | 0.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.96% | 11.45% | 6.95% | 7.44% | 0.51% |
| Cost of Revenue | 14.08% | 19.84% | 17.34% | 26.88% | -0.26% |
| Gross Profit | 8.90% | 9.41% | 5.02% | 3.43% | 0.71% |
| SG&A Expenses | 19.85% | 9.58% | -9.56% | -11.02% | 2.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 46.02% | 40.27% | 320.65% | 351.22% | 253.12% |
| Total Operating Expenses | 12.73% | 9.19% | 18.06% | 19.15% | 51.26% |
| Operating Income | -18.58% | -4.34% | -95.12% | -96.23% | -2,410.31% |
| Income Before Tax | -60.00% | -58.69% | -69.83% | -61.72% | -650.71% |
| Income Tax Expenses | 433.61% | 796.32% | -64.47% | -117.38% | -181.54% |
| Earnings from Continuing Operations | -76.93% | -76.39% | -26.46% | 29.76% | -786.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.93% | -76.39% | -26.46% | 29.76% | -786.05% |
| EBIT | -18.58% | -4.34% | -95.12% | -96.23% | -2,410.31% |
| EBITDA | -13.51% | -3.80% | -86.97% | -121.37% | -618.23% |
| EPS Basic | -72.00% | -75.22% | -26.18% | 29.71% | -772.17% |
| Normalized Basic EPS | -63.24% | -80.81% | -121.14% | -74.02% | -472.34% |
| EPS Diluted | -71.31% | -74.42% | -24.80% | 29.88% | -810.16% |
| Normalized Diluted EPS | -62.67% | -80.03% | -115.10% | -68.79% | -488.26% |
| Average Basic Shares Outstanding | 1.61% | 0.24% | -0.09% | 0.36% | 0.17% |
| Average Diluted Shares Outstanding | 1.29% | -0.07% | -0.53% | 0.16% | -0.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |